Physician profile
Frank Torres
NPI 1972500551
$1,911.73
in general payments reported to CMS, 2019-2025
29 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $136 · 2021: $39.48 · 2022: $297 · 2023: $273 · 2024: $532 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,089.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $601.52 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $298.19 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Amarin Pharma, INC. | $137.47 | 2019-2020 | |
| Exact Sciences Corporation | $102.08 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $85.56 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Dexcom, INC. | $70.07 | 2024-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $68.00 | 2019-2025 | |
| Sanofi Pasteur INC. | $46.09 | 2019-2025 | |
| Nevro Corp. | $45.69 | 2022-2024 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.69 | 2023-2024 | Jardiance |
| Abbvie INC. | $40.57 | 2023 | Vraylar, Linzess, Viberzi |
| Astrazeneca Pharmaceuticals LP | $35.67 | 2025 | Fasenra |
| Otsuka America Pharmaceutical, INC. | $34.92 | 2025 | Rexulti |
| Paratek Pharmaceuticals, INC. | $29.18 | 2023 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $27.95 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $25.79 | 2019 | |
| Intuitive Surgical, INC. | $23.33 | 2019 | |
| Inspire Medical Systems, INC. | $22.87 | 2024 | Inspire |
| Novartis Pharmaceuticals Corporation | $21.66 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.74 | 2019 | |
| Abbott Laboratories | $18.14 | 2023 | Freestyle Libre 3 |
| Astellas Pharma US INC | $17.31 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.87 | 2024 | Voquezna |
| Insulet Corporation | $15.27 | 2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $15.17 | 2024 | Keveyis |
| Amgen INC. | $14.75 | 2024 | Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $14.01 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.64 | 2024 | |
| Hologic Sales and Service, LLC | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.